{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:56:31Z","timestamp":1783115791352,"version":"3.54.6"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The COVID-19 pandemic affected healthcare management for people with multiple sclerosis (PwMS), leading to alterations in disease-modifying therapies (DMTs) due to concerns about COVID-19 outcomes and vaccine efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To compare DMT prescription patterns in PwMS before, during, and after the COVID-19 pandemic.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>PwMS from the German MS Register, between 2019 and 2024, either newly diagnosed (Cohort A) or who discontinued or switched DMT (Cohort B), were analyzed over a follow-up period of 3\u00a0months. Data from the pre-pandemic period were compared to early-, late-, and post-pandemic periods. DMTs were categorized as medium efficacy (meDMT) or high efficacy (heDMT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In Cohort A (<jats:italic>n<\/jats:italic>\u2009=\u20091810), pre-pandemic 46% had no DMT\u00a0within 3 months of diagnosis, 39% received meDMT, and 15% heDMT (7.5% B cell-depleting therapies (BCD)). heDMT use increased during later periods (\u201cearly\u201d 19%, \u201clate\u201d 29%, \u201cpost\u201d 41%), with a shift toward BCD. In cohort B (<jats:italic>n<\/jats:italic>\u2009=\u20094246), pre-pandemic 47% paused DMT, 19% switched to meDMT, and 34% to heDMT (17% BCD). heDMT use also rose during the pandemic (\u201cearly\u201d 37%, \u201clate\u201d 47%, \u201cpost\u201d 48%), with increased BCD use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There were no delays in DMT initiation or resumption during the pandemic with a notable increase in heDMT and BCD use, reflecting growing confidence in these treatment options.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-13010-6","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T07:54:08Z","timestamp":1743234848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7296-4349","authenticated-orcid":false,"given":"Agni-Maria","family":"Konitsioti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ellenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Stahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Rommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"13010_CR1","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/nejmoa2002032","volume":"382","author":"W-J Guan","year":"2020","unstructured":"Guan W-J, Ni Z-Y, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708\u20131720. https:\/\/doi.org\/10.1056\/nejmoa2002032","journal-title":"N Engl J Med"},{"key":"13010_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000835","volume":"7","author":"E Parrotta","year":"2020","unstructured":"Parrotta E, Kister I, Charvet L et al (2020) COVID-19 outcomes in MS: observational study of early experience from NYU multiple sclerosis comprehensive care center. Neurol Neuroimmunol Neuroinflammation 7:e835. https:\/\/doi.org\/10.1212\/nxi.0000000000000835","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"13010_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre C, Collongues N, Stankoff B et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77:1079\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2581","journal-title":"JAMA Neurol"},{"key":"13010_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102472","volume":"46","author":"MA Sahraian","year":"2020","unstructured":"Sahraian MA, Azimi A, Navardi S et al (2020) Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 46:102472. https:\/\/doi.org\/10.1016\/j.msard.2020.102472","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR5","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1111\/ene.15072","volume":"28","author":"NN Kleineberg","year":"2021","unstructured":"Kleineberg NN, Knauss S, G\u00fclke E et al (2021) Neurological symptoms and complications in predominantly hospitalized COVID-19 patients: results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS). Eur J Neurol 28:3925\u20133937. https:\/\/doi.org\/10.1111\/ene.15072","journal-title":"Eur J Neurol"},{"key":"13010_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/13524585211005339","volume":"28","author":"E Portaccio","year":"2021","unstructured":"Portaccio E, Fonderico M, Hemmer B et al (2021) Impact of COVID-19 on multiple sclerosis care and management: results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Mult Scler J 28:132\u2013138. https:\/\/doi.org\/10.1177\/13524585211005339","journal-title":"Mult Scler J"},{"key":"13010_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241103","volume":"15","author":"H Alnajashi","year":"2020","unstructured":"Alnajashi H, Jabbad R (2020) Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic. PLoS ONE 15:e0241103. https:\/\/doi.org\/10.1371\/journal.pone.0241103","journal-title":"PLoS ONE"},{"key":"13010_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1177\/1352458520948231","volume":"26","author":"BP Moss","year":"2020","unstructured":"Moss BP, Mahajan KR, Bermel RA et al (2020) Multiple sclerosis management during the COVID-19 pandemic. Mult Scler J 26:1163\u20131171. https:\/\/doi.org\/10.1177\/1352458520948231","journal-title":"Mult Scler J"},{"key":"13010_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1177\/1352458520931785","volume":"26","author":"J Sastre-Garriga","year":"2020","unstructured":"Sastre-Garriga J, Tintor\u00e9 M, Montalban X (2020) Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Mult Scler J 26:1153\u20131156. https:\/\/doi.org\/10.1177\/1352458520931785","journal-title":"Mult Scler J"},{"key":"13010_CR10","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1136\/annrheumdis-2020-218400","volume":"81","author":"P Aries","year":"2022","unstructured":"Aries P, Iking-Konert C (2022) No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany). Ann Rheum Dis 81:e245\u2013e245. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218400","journal-title":"Ann Rheum Dis"},{"key":"13010_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102580","volume":"117","author":"JC Sarmiento-Monroy","year":"2021","unstructured":"Sarmiento-Monroy JC, Espinosa G, Londo\u00f1o M-C et al (2021) A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. J Autoimmun 117:102580. https:\/\/doi.org\/10.1016\/j.jaut.2020.102580","journal-title":"J Autoimmun"},{"key":"13010_CR12","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/ene.14555","volume":"28","author":"G Bsteh","year":"2021","unstructured":"Bsteh G, Bitschnau C, Hegen H et al (2021) Multiple sclerosis and COVID-19: How many are at risk? Eur J Neurol 28:3369\u20133374. https:\/\/doi.org\/10.1111\/ene.14555","journal-title":"Eur J Neurol"},{"key":"13010_CR13","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1111\/ene.14690","volume":"28","author":"A Zabalza","year":"2021","unstructured":"Zabalza A, C\u00e1rdenas-Robledo S, Tagliani P et al (2021) COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol 28:3384\u20133395. https:\/\/doi.org\/10.1111\/ene.14690","journal-title":"Eur J Neurol"},{"key":"13010_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD et al (2021) Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of Patients With Multiple Sclerosis. JAMA Neurol 78:699\u2013708. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0688","journal-title":"JAMA Neurol"},{"key":"13010_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009507.10.1212\/wnl.0000000000009507","author":"W Brownlee","year":"2020","unstructured":"Brownlee W, Bourdette D, Broadley S et al (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000009507.10.1212\/wnl.0000000000009507","journal-title":"Neurology"},{"key":"13010_CR16","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000761","volume":"7","author":"JR Berger","year":"2020","unstructured":"Berger JR, Brandstadter R, Bar-Or A (2020) COVID-19 and MS disease-modifying therapies. Neurol - Neuroimmunol Neuroinflammation 7:e761. https:\/\/doi.org\/10.1212\/nxi.0000000000000761","journal-title":"Neurol - Neuroimmunol Neuroinflammation"},{"key":"13010_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Rossi ND, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89:780\u2013789. https:\/\/doi.org\/10.1002\/ana.26028","journal-title":"Ann Neurol"},{"key":"13010_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102195","volume":"43","author":"F Safavi","year":"2020","unstructured":"Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195. https:\/\/doi.org\/10.1016\/j.msard.2020.102195","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103912","volume":"63","author":"G Bsteh","year":"2022","unstructured":"Bsteh G, Riedl K, Krajnc N et al (2022) Has the pandemic changed treatment strategy in multiple sclerosis? Mult Scler Relat Disord 63:103912. https:\/\/doi.org\/10.1016\/j.msard.2022.103912","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1007\/s00415-021-10958-z","volume":"269","author":"A Cobo-Calvo","year":"2022","unstructured":"Cobo-Calvo A, Zabalza A, R\u00edo J et al (2022) Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. J Neurol 269:1764\u20131772. https:\/\/doi.org\/10.1007\/s00415-021-10958-z","journal-title":"J Neurol"},{"key":"13010_CR21","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1007\/s00415-020-10045-9","volume":"267","author":"FJ Mateen","year":"2020","unstructured":"Mateen FJ, Rezaei S, Alakel N et al (2020) Impact of COVID-19 on U.S. and Canadian neurologists\u2019 therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol 267:3467\u20133475. https:\/\/doi.org\/10.1007\/s00415-020-10045-9","journal-title":"J Neurol"},{"key":"13010_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104575","volume":"71","author":"R Zaheer","year":"2023","unstructured":"Zaheer R, Amin R, Riddick L et al (2023) Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis. Mult Scler Relat Disord 71:104575. https:\/\/doi.org\/10.1016\/j.msard.2023.104575","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR23","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s00415-020-10309-4","volume":"268","author":"P Preziosa","year":"2021","unstructured":"Preziosa P, Rocca MA, Nozzolillo A et al (2021) COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J Neurol 268:2697\u20132699. https:\/\/doi.org\/10.1007\/s00415-020-10309-4","journal-title":"J Neurol"},{"key":"13010_CR24","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40120-023-00520-6","volume":"12","author":"F Carlini","year":"2023","unstructured":"Carlini F, Lusi V, Rizzi C et al (2023) Cladribine tablets mode of action, learning from the pandemic: a narrative review. Neurol Ther 12:1477\u20131490. https:\/\/doi.org\/10.1007\/s40120-023-00520-6","journal-title":"Neurol Ther"},{"key":"13010_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12883-021-02421-3","volume":"21","author":"CG Chisari","year":"2021","unstructured":"Chisari CG, Toscano S, Arena S et al (2021) Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurol 21:462. https:\/\/doi.org\/10.1186\/s12883-021-02421-3","journal-title":"BMC Neurol"},{"key":"13010_CR26","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1007\/s00415-024-12518-7","volume":"271","author":"AP Lal","year":"2024","unstructured":"Lal AP, Foong YC, Sanfilippo PG et al (2024) A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. J Neurol 271:5813\u20135824. https:\/\/doi.org\/10.1007\/s00415-024-12518-7","journal-title":"J Neurol"},{"key":"13010_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ncl.2023.06.006","volume":"42","author":"JD Krett","year":"2024","unstructured":"Krett JD, Salter A, Newsome SD (2024) Era of COVID-19 in multiple sclerosis care. Neurol Clin 42:319\u2013340. https:\/\/doi.org\/10.1016\/j.ncl.2023.06.006","journal-title":"Neurol Clin"},{"key":"13010_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.19766","volume":"6","author":"E Januel","year":"2023","unstructured":"Januel E, Hajage D, Labauge P et al (2023) Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open 6:e2319766. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.19766","journal-title":"JAMA Netw Open"},{"key":"13010_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10096-024-04776-0","volume":"43","author":"E Feuth","year":"2024","unstructured":"Feuth E, Nieminen V, Palom\u00e4ki A et al (2024) Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy. Eur J Clin Microbiol Infect Dis 43:723\u2013734. https:\/\/doi.org\/10.1007\/s10096-024-04776-0","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"13010_CR30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1136\/annrheumdis-2020-219498","volume":"80","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80:930\u2013942. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219498","journal-title":"Ann Rheum Dis"},{"key":"13010_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103358","volume":"57","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I, Ponzano M, Signori A et al (2022) Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis. Mult Scler Relat Disord 57:103358. https:\/\/doi.org\/10.1016\/j.msard.2021.103358","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","volume":"16","author":"C Korsukewitz","year":"2020","unstructured":"Korsukewitz C, Reddel SW, Bar-Or A et al (2020) Neurological immunotherapy in the era of COVID-19 \u2014 looking for consensus in the literature. Nat Rev Neurol 16:493\u2013505. https:\/\/doi.org\/10.1038\/s41582-020-0385-8","journal-title":"Nat Rev Neurol"},{"key":"13010_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102073","volume":"39","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G, Hawkes C, Lechner-Scott J et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 39:102073. https:\/\/doi.org\/10.1016\/j.msard.2020.102073","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR34","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51408","volume":"8","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, Salvetti M, Labauge P et al (2021) DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol 8:1738\u20131744. https:\/\/doi.org\/10.1002\/acn3.51408","journal-title":"Ann Clin Transl Neurol"},{"key":"13010_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3238\/arztebl.2008.0113","volume":"105","author":"P Flachenecker","year":"2008","unstructured":"Flachenecker P, Stuke K, Elias W et al (2008) Multiple Sclerosis Registry in Germany\u2014results of the Extension Phase 2005\/2006. Dtsch \u00c4rzteblatt Int 105:113\u2013119. https:\/\/doi.org\/10.3238\/arztebl.2008.0113","journal-title":"Dtsch \u00c4rzteblatt Int"},{"key":"13010_CR36","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1007\/s00415-009-5257-5","volume":"256","author":"K Stuke","year":"2009","unstructured":"Stuke K, Flachenecker P, Zettl UK et al (2009) Symptomatology of MS: results from the German MS Registry. J Neurol 256:1932\u20131935. https:\/\/doi.org\/10.1007\/s00415-009-5257-5","journal-title":"J Neurol"},{"key":"13010_CR37","doi-asserted-by":"publisher","first-page":"13340","DOI":"10.1038\/s41598-021-92722-x","volume":"11","author":"L-M Ohle","year":"2021","unstructured":"Ohle L-M, Ellenberger D, Flachenecker P et al (2021) Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. Sci Rep 11:13340. https:\/\/doi.org\/10.1038\/s41598-021-92722-x","journal-title":"Sci Rep"},{"key":"13010_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001024","volume":"8","author":"G Arrambide","year":"2021","unstructured":"Arrambide G, Llaneza-Gonz\u00e1lez M\u00c1, Fran\u00e7a LC-F et al (2021) SARS-CoV-2 infection in multiple sclerosis. Neurol Neuroimmunol Neuroinflammation 8:e1024. https:\/\/doi.org\/10.1212\/nxi.0000000000001024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"13010_CR39","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/jnnp-2021-328340","volume":"93","author":"T Williams","year":"2022","unstructured":"Williams T, Mishra R, Bharkhada B et al (2022) Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study. J Neurol, Neurosurg Psychiatry 93:1229\u20131230. https:\/\/doi.org\/10.1136\/jnnp-2021-328340","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"13010_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577627","volume":"357","author":"S Reyes","year":"2021","unstructured":"Reyes S, Cunningham AL, Kalincik T et al (2021) Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: an international consensus statement. J Neuroimmunol 357:577627. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577627","journal-title":"J Neuroimmunol"},{"key":"13010_CR41","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis SA, Kakara M, Painter MM et al (2021) Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat Med 27:1990\u20132001. https:\/\/doi.org\/10.1038\/s41591-021-01507-2","journal-title":"Nat Med"},{"key":"13010_CR42","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1007\/s00415-023-11935-4","volume":"270","author":"R Spierer","year":"2023","unstructured":"Spierer R, Lavi I, Bloch S et al (2023) Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies. J Neurol 270:4632\u20134639. https:\/\/doi.org\/10.1007\/s00415-023-11935-4","journal-title":"J Neurol"},{"key":"13010_CR43","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/jnnp-2022-330757","volume":"94","author":"F Novak","year":"2023","unstructured":"Novak F, Bajwa HM, Coia JE et al (2023) Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses. J Neurol, Neurosurg Psychiatry 94:934\u2013937. https:\/\/doi.org\/10.1136\/jnnp-2022-330757","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"13010_CR44","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1177\/13524585221102918","volume":"28","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I, Cordioli C, Stromillo ML et al (2022) Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies. Mult Scler J 28:2106\u20132111. https:\/\/doi.org\/10.1177\/13524585221102918","journal-title":"Mult Scler J"},{"key":"13010_CR45","doi-asserted-by":"publisher","first-page":"104042","DOI":"10.1016\/j.ebiom.2022.104042","volume":"80","author":"MP Sormani","year":"2022","unstructured":"Sormani MP, Schiavetti I, Inglese M et al (2022) Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine 80:104042. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104042","journal-title":"EBioMedicine"},{"key":"13010_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103737","volume":"62","author":"S Satyanarayan","year":"2022","unstructured":"Satyanarayan S, Safi N, Sorets T et al (2022) Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. Mult Scler Relat Disord 62:103737. https:\/\/doi.org\/10.1016\/j.msard.2022.103737","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439","volume":"45","author":"JR Ciotti","year":"2020","unstructured":"Ciotti JR, Valtcheva MV, Cross AH (2020) Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord 45:102439. https:\/\/doi.org\/10.1016\/j.msard.2020.102439","journal-title":"Mult Scler Relat Disord"},{"key":"13010_CR48","doi-asserted-by":"publisher","first-page":"175628642110128","DOI":"10.1177\/17562864211012835","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S et al (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012836. https:\/\/doi.org\/10.1177\/17562864211012835","journal-title":"Ther Adv Neurol Disord"},{"key":"13010_CR49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/vaccines12030296","volume":"12","author":"M Schraad","year":"2024","unstructured":"Schraad M, Runkel S, Hitzler W et al (2024) Long-term observation of SARS-CoV-2 vaccination response upon high efficacy treatment in multiple sclerosis\u2014a real-world scenario. Vaccines 12:296. https:\/\/doi.org\/10.3390\/vaccines12030296","journal-title":"Vaccines"},{"key":"13010_CR50","doi-asserted-by":"publisher","DOI":"10.12659\/msm.942992","volume":"30","author":"E Komoni","year":"2023","unstructured":"Komoni E, Jashari F, Boshnjaku D et al (2023) Risk factors and clinical outcomes of COVID-19 infection in multiple sclerosis patients: a retrospective study from a single center in Kosovo. M\u00e9d Sci Monit 30:e942992. https:\/\/doi.org\/10.12659\/msm.942992","journal-title":"M\u00e9d Sci Monit"},{"key":"13010_CR51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/nejmoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383:546\u2013557. https:\/\/doi.org\/10.1056\/nejmoa1917246","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T10:09:37Z","timestamp":1744970977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["13010"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13010-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"5 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SL and DE have nothing to disclose. AK has received a study grant from Novartis. AS has no personal pecuniary interests to disclose, other than being the lead of the German MS Registry, which receives (project) funding from a range of public and corporate sponsors, recently including The German Ministry The German Innovation Fund (G-BA), The German Retirement Insurance, The German MS Trust, The German MS Society, Biogen GmbH, BristolMyersSquibb, Merck Healthcare Germany GmbH, Novartis Pharma GmbH, Roche Pharma AG, and TG Therapeutics. PSR has received speaking fees, honoraria from advisory boards, and\/or financial support for research activities from A-Med, Alexion\/AstraZeneca, Almirall, AMGEN, Amicus, Biogen, Merck, neuraxpharm, Novartis, Roche, Sandoz, Sanofi, and Teva. JH serves as president of the German MS Society, federal association, which receives funding from a range of public and corporate sponsors, recently including BMG, G-BA, The German MS Trust, Biogen, BMS, Merck Serono, Novartis, Roche, Sanofi, and Viatris. CW has received institutional support from Novartis, Alexion, Sanofi Genzyme, Biogen, Merck, Janssen, Bayer, and Roche. He has received personal honoraria for teaching lectures from Biontech, Medpoint Medizinkommunikations, F&U confirm, Privatinstitut f\u00fcr Klinikmanagement, and The Royal College Of Physicians, and for consulting from Wuesthoff\u2009+\u2009Wuesthoff and Bristows LLP.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The registration of the GMSR proceeded at the German Registry for Clinical Trials (Deutsches Register Klinischer Studien [DRKS]; No. DRKS00011257). The initial ethics vote was approved by University of W\u00fcrzburg\u2019s institutional review board (permit No. 142\/12).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}],"article-number":"294"}}